Sentinel lymph node biopsy in XXXX : Systematic review and technology update.

@entity1 @entity0 @entity5 @entity235 @entity1600 @entity150 @entity3 @entity320
A @entity1600 ( @entity1600 ) is the first lymph node to drain a solid @entity5 and likely the first place @entity3 will travel. @entity1600 biopsy has been well established as a staging tool for @entity320 and @entity0 to guide lymph node dissection (LND); its utility in @entity150 is debated. We performed a systematic search of PubMed for both @entity1 and animal studies that looked at @entity1600 detection in cases of @entity150 . We identified a total of nine studies that assessed a variety of imaging techniques to identify SLNs in @entity1 with @entity150 . Eight studies investigated @entity1 @entity1 while one looked at animal ( @entity235 ) models. Seven studies representing 156 @entity1 noted the negative predictive value of the @entity1600 to predict a @entity3 free state was 92% (92/100). The @entity1600 biopsy was less accurate in metastatic @entity1 with a positive predictive value of only 77% (43/56) with a false negative range of in individual studies of 0-19%. Clinically, positive nodes routinely do not take up the pharmaceutical agent for @entity1600 . Therefore, @entity1600 biopsy is a promising concept with a 92% negative predictive value; however, the false negative rates are high which may be improved by standardizing populations and indications. Novel technologies are improving the detection of @entity1600 and may provide the surgeon with an improved ability to detect micrometastasis, guide surgery, and reduce @entity1 morbidity.
